Log in

OTCMKTS:BTCYBiotricity Stock Price, Forecast & News

+0.02 (+1.32 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $1.54
50-Day Range
MA: $1.23
52-Week Range
Now: $1.54
Volume33,769 shs
Average Volume89,926 shs
Market Capitalization$56.03 million
P/E RatioN/A
Dividend YieldN/A
Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, focuses on providing biometric data monitoring solutions in the United States. The company focuses to deliver remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It is developing Bioflux mobile cardiac telemetry solution that provides recurring reimbursements to doctors, hospitals, and independent diagnostic testing facilities; revenue model that fits within the established insurance billing practices; built-in cellular connectivity; and motion tracking to detect exercise, activity, and disorientation. The company is also developing Biolife, a health and lifestyle solution for individuals. It has a collaboration agreement with the University of Calgary to determine the predictive value of electrocardiogram readings in preventative healthcare applications. Biotricity, Inc. is based in Redwood City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Electric services
Current SymbolOTCMKTS:BTCY



Sales & Book Value

Annual SalesN/A



Market Cap$56.03 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BTCY News and Ratings via Email

Sign-up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter.

Biotricity (OTCMKTS:BTCY) Frequently Asked Questions

How has Biotricity's stock been impacted by COVID-19 (Coronavirus)?

Biotricity's stock was trading at $1.2250 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BTCY shares have increased by 25.7% and is now trading at $1.54. View which stocks have been most impacted by Coronavirus.

Has Biotricity been receiving favorable news coverage?

News stories about BTCY stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biotricity earned a daily sentiment score of -3.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutBiotricity.

Who are some of Biotricity's key competitors?

What other stocks do shareholders of Biotricity own?

Who are Biotricity's key executives?

Biotricity's management team includes the following people:
  • Mr. Waqaas Al-Siddiq, Founder, Pres, CEO & Chairman (Age 34)
  • Mr. John Ayanoglou, Chief Financial Officer (Age 53)
  • Mr. Casey Shattuck, Global VP of Sales
  • Mr. Amir Ali, Chief Devel. Officer
  • Mr. Spencer LaDow, VP of Engineering

What is Biotricity's stock symbol?

Biotricity trades on the OTCMKTS under the ticker symbol "BTCY."

How do I buy shares of Biotricity?

Shares of BTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biotricity's stock price today?

One share of BTCY stock can currently be purchased for approximately $1.54.

How big of a company is Biotricity?

Biotricity has a market capitalization of $56.03 million.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.